Cover Image
市場調查報告書

全球肺癌疫苗市場·開發平台預測

Global Lung Cancer Vaccine Market & Pipeline Outlook 2022

出版商 KuicK Research 商品編碼 324798
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球肺癌疫苗市場·開發平台預測 Global Lung Cancer Vaccine Market & Pipeline Outlook 2022
出版日期: 2016年12月22日 內容資訊: 英文 150 Pages
簡介

本報告提供全球肺癌疫苗市場相關調查分析,以進行中的臨床/非臨床趨勢為焦點,提供臨床試驗,疫苗開發臨床考察,競爭情形等系統性資訊。

第1章 所謂癌症疫苗

第2章 癌症疫苗的機制

  • 個體遺傳型
  • 細胞性
  • 神經節苷脂抗原
  • 胜肽
  • 腫瘤宿主相互作用

第3章 肺癌增生概要

  • 肺癌浸潤
  • 肺癌轉移

第4章 肺癌疫苗的機制

  • 肺癌疫苗的機制
  • 使用肺癌疫苗的理論根據

第5章 肺癌疫苗的臨床試驗

第6章 全球肺癌發病率

  • 美國
  • 歐洲
  • 亞洲
  • 其他

第7章 全球肺癌疫苗市場概要

  • 目前市場方案
  • 全球肺癌疫苗的開發平台概要
  • 全球肺癌疫苗市場未來發展預測

第8章 乳癌的個體化疫苗需求

第9章 肺癌疫苗的臨床實驗平台:各企業,各期

  • 前臨床
  • 第一階段
  • 第二階段

第10章 非小細胞肺癌疫苗的臨床實驗平台:各企業,各期

  • 研究
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段

第11章 小細胞肺癌疫苗的臨床實驗平台:各企業,各期

  • 第二階段

第12章 已上市的肺癌疫苗臨床·專利考察

第13章 沒有開發報告/中止的肺癌疫苗的臨床實驗平台:各企業,各適應症,各期

  • 沒有開發報告
  • 中止
  • 中斷

第14章 競爭情形

  • Argos Therapeutics
  • Boehringer Ingelheim
  • Cadila Pharmaceuticals
  • CureVac
  • Eli Lily
  • Galaxo
  • ImClone Systems
  • Inovio Pharmaceuticals
  • Merck
  • NewLink Genetics
  • Northwest Biotherapeutics
  • 小野藥品工業
  • Oncothyreon Incorporation
  • OSE Immunotherapeutics

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

“Global Lung Cancer Vaccine Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the global lung cancer vaccine market. Currently there are 3 lung cancer vaccines commercially available in the market. This report analyzes the ongoing clinical trial of 30 lung cancer vaccines in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the lung cancer vaccines. Currently there are 9 lung cancer vaccines in advance Phase-II clinical trials followed by 8 vaccines Phase-I/II trials.

Lung cancer is emerging as one of the most lethal malignancy having high morbidity and mortality rates across the world. High mortality rates, high unmet medical necessities and modest efficacy of presently available lung cancer therapeutics have encouraged the demand for better and efficient lung cancer vaccines. More funds are being diverted into research and development segment to come up with lung cancer vaccine having high safety and efficacy profiles. Pharmaceutical companies have recognized the marketing potential of these vaccines in generating significant revenues and providing efficient medical care to patients across the world. Lung cancer vaccine market is largely untapped and offers significant opportunities to pharmaceutical companies to occupy large market shares across the globe.

At present majority of the lung cancer vaccines are in experimental stage and are still stuck in clinical trials due to which large unmet medical demands are still to be fulfilled. Boehringer Ingelheim and CureVac are developing lung cancer vaccine called CV9202 for the treatment of lung cancer which is at higher phase of clinical trials. GlaxoSmithKline is developing MAGE-A3 lung cancer vaccine which is also under investigation for other malignancies. Cell Genesys pharmaceutical company is developing GVAX for lung cancer and many clinical end points have been achieved during investigation.

Early market introduction of these drugs will be the major factor responsible for the increased marketing potential. Over time, they are expected to generate significant revenues owing to their safety and efficacy levels but till then this gap will be filled by other therapeutics. Further, those lung cancer vaccines which will make late entry have to face competition with previously marketed lung cancer vaccines giving them severe competition. This shows that pharmaceutical companies have to introduce their products in market as soon as possible to occupy major market shares across the globe. Thus, impact of early entrant will be more in global market and help them to generate significant revenues for some time before entry of worthy competitors.

Many pharmaceutical companies have already introduces cancer vaccines in global market and lung cancer segment is expected to get its first contender in coming years. Addition of lung cancer vaccines in this segment will further increase the size of global cancer vaccine market. Several other products belonging to different cancer indication will be entering in the global market leading to further increase in the market size. Advent of lung cancer vaccines is expected to improve this situation by increasing present survival rates and improve quality of life. Introduction of lung cancer vaccines are expected to gain major market shares among other cancer vaccines due to large patient population as compared to other disease indication.

Table of Contents

1. What are Cancer Vaccines?

2. Mechanism of Cancer Vaccines

  • 2.1. Idiotype Cancer Vaccine Mechanism
  • 2.2. Cellular Cancer Vaccines Mechanism
  • 2.3. Ganglioside Antigens based Cancer Vaccines Mechanism
  • 2.4. Peptide Cancer Vaccine Mechanism
  • 2.5. Tumor Host Interaction Cancer Vaccine Mechanism

3. Overview of Lung Cancer Proliferation

  • 3.1. Lung Cancer Invasion
    • 3.1.1. Transformation of Normal Cell into Cancerous Cell
    • 3.1.2. Tumor Heterogeneity & Cancer Stem Cells
    • 3.1.3. Dissemination of Tumor Cell & Cell Motility
  • 3.2. Lung Cancer Metastasis
    • 3.2.1. Angiogenesis & Lymphangiogenesis
    • 3.2.2. Intravasation, Circulation & Extravasation

4. Lung Cancer Vaccine Mechanism

  • 4.1. Mechanism of Lung Cancer Vaccination
  • 4.2. Rationale for Using Lung Cancer Vaccines
    • 4.2.1. Regulatory T- Lymphocytes (Tregs)
    • 4.2.2. Macrophages

5. Clinical Trials of Lung Cancer Vaccines

6. Global Lung Cancer Incidence Rate

  • 6.1. U.S
  • 6.2. Europe
  • 6.3. Asia
  • 6.4. Rest of the World

7. Global Lung Cancer Vaccine Market Overview

  • 7.1. Current Market Scenario
  • 7.2. Global Lung Cancer Vaccine Pipeline Overview
  • 7.3. Global Lung Cancer Vaccine Market Future Prospects

8. Need for Personalized Breast Cancer Vaccines

9. Lung Cancer Vaccine Clinical Pipeline by Company & Phase

  • 9.1. Preclinical
  • 9.2. Phase-I
  • 9.3. Phase-II

10. Non Small Cell Lung Cancer Vaccine Clinical Pipeline by Company & Phase

  • 10.1. Research
  • 10.2. Preclinical
  • 10.3. Phase-I
  • 10.4. Phase-I/II
  • 10.5. Phase-II
  • 10.6. Phase-II/III
  • 10.7. Phase-III

11. Small cell lung Cancer Vaccine Clinical Pipeline by Company & Phase

  • 11.1. Phase-II

12. Marketed Lung Cancer Vaccine Clinical & Patent Insight

  • 12.1. Epidermal Growth Factor Cancer Vaccine
  • 12.2. Mycidac-C™
  • 12.3. Racotumomab (Vaxira)

13. No Development Reported & Discontinued Lung Cancer Vaccine Clinical Pipeline by Company, Indication & Phase

  • 13.1. No Development Reported
  • 13.2. Discontinued
  • 13.3. Suspended

14. Competitive Landscape

  • 14.1. Argos Therapeutics
  • 14.2. Boehringer Ingelheim
  • 14.3. Cadila Pharmaceuticals
  • 14.4. CureVac
  • 14.5. Eli Lily
  • 14.6. Galaxo
  • 14.7. ImClone Systems
  • 14.8. Inovio Pharmaceuticals
  • 14.9. Merck
  • 14.10. NewLink Genetics
  • 14.11. Northwest Biotherapeutics
  • 14.12. Ono Pharmaceutical
  • 14.13. Oncothyreon Incorporation
  • 14.14. OSE Immunotherapeutics

List of Figures

  • Figure 1-1: Categorization & Function of Cancer Vaccines
  • Figure 2-1: Classification of Different Types of Cancer vaccines
  • Figure 3-1: Major Steps Involved in Cancer Invasiveness
  • Figure 4-1: Mechanism of Lung Cancer Vaccination
  • Figure 6-1: US - Lung Cancer New Incidence & Deaths, 2016
  • Figure 6-2: US - Lung Cancer New Incidence by Gender, 2016
  • Figure 6-3: US - Lung Cancer Deaths by Gender, 2016
  • Figure 6-4: Japan - Lung Cancer New Incidence & Deaths, 2016
  • Figure 6-5: Japan - Lung Cancer New Incidence by Gender, 2016
  • Figure 6-6: Japan - Lung Cancer Deaths by Gender, 2016
  • Figure 6-7: China - Lung Cancer Patients, 2016 & 2022
  • Figure 6-8: India - Lung Cancer New Incidence, 2016 & 2022
  • Figure 6-9: Canada - Lung Cancer Deaths by Gender, 2016
  • Figure 7-1: Global Lung Cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022
  • Figure 7-2: Global Lung Cancer Vaccine Clinical Pipeline by Phase (Numbers), 2016 till 2022
  • Figure 7-3: Global Non-small cell lung cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022
  • Figure 7-4: Global Non-small cell lung cancer Vaccine Clinical Pipeline by Phase (Number), 2016 till 2022
  • Figure 7-5: Global Lung Cancer Vaccine Clinical Pipeline by Phase (%), 2016 till 2022
  • Figure 7-6: Global Lung Cancer Vaccine Clinical Pipeline by Phase (Numbers), 2016 till 2022
  • Figure 8-1: Overview of Personalized Cancer Vaccines Development
  • Figure 8-2: Methodology for the Development of Personalized Cancer Vaccine
  • Figure 8-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
  • Figure 14-1: Inovio Pharmaceuticals Clinical Pipeline
  • Figure 14-2: NewLink Genetics Corporation Clinical Pipeline
  • Figure 14-3: Northwest Biotherapeutics Clinical Pipeline
Back to Top